Press Room

    Back

    Press Release - December 04, 2006

    Leading Virologist Dr. Clive Patience Appointed to Help Guide the Development of Sernova's Proposed Diabetes Product


    Kelowna, B.C. -- Sernova Corp. ("Sernova") is pleased to announce that Dr. Clive Patience Ph.D. has joined its Scientific Advisory Board ("SAB") to assist the company with its diabetes product development.

    "Dr. Patience is one of the world's leading experts on biological safety of xenotransplantation, and is a supporter of Sernova's emerging diabetes technology." stated Dr. David White, Chair of Sernova's SAB. "Our research team will be enhanced by his intimate understanding of biological safety, while his knowledge of the FDA process will assist us in moving this technology to the clinic."

    Dr. Patience is currently the Associate Director of Bioanalytical Quality Control at Biogen Idec. Inc. (NASDAQ: BIIB) in Cambridge Massachusetts. For several years previously he directed research on porcine retroviruses and herpesviruses, and in a 3 year study demonstrated the acceptable microbiological safety of pig to non-human primate transplants. He has also been an invited speaker to FDA safety committees..

    About Dr. Patience Dr. Patience obtained his Ph.D in virology from the University of London while working as a research scientist at the Institute of Cancer Research in London England, Much of his research focused on the biology of HIV, porcine endogenous retroviruses, and retroviral/adenoviral gene therapy vectors. He later accepted a position in Massachusetts as Director of Microbiological Safety with Immerge Bio Therapeutics, a world leader in research to genetically modify pigs for organ transplants. In 2004 he joined Biogen Idec as a Senior Scientist before ascending to his current position. His research has been published in many peer reviewed journals including Nature Medicine, the Journal of Virology and the American Journal of Transplantation. Dr. Patience has also contributed chapters to several medical books.

    About Sernova Sernova Corp. is a Canadian based, health sciences company focused on commercializing medical technologies and currently working to cure insulin dependent diabetes. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. Over $100 billion per year is spent in the US on treating diabetes and its complications.

    This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

    ON BEHALF OF THE BOARD

    "Justin Leushner" Justin Leushner, President

    For further information contact: TEL: (888) 318-7062 FAX: (250) 868-8493 info@sernovacorp.com www.sernovacorp.com

    Phil Morehouse Executive Vice President Sernova Corp.

    THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

    Back



    Press Releases from:

    2017 2016 2015 2014 2013 2012 2011

    2010 2009 2008 2007 2006 2005 2004

    2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs

    Link

    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance

    PDF

    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario

    Link

    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Publisher: StockInterview.com
    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Publisher: StockInterview.com
    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Publisher: StockInterview.com
    Author: James Finch

    Presentation and Video

    September 11, 2017

    Sernova Fact Sheet

    September 11, 2017

    Sernova's 2017 Corporate Presentation

    PDF Presentation

    Subscribe to Sernova News

Subscribe to our News Dispatch Service

* indicates required




Latest Video and Presentation


Sernova Fact Sheet - / September 11, 2017 Open


Sernova's 2017 Corporate Presentation - PDF Presentation / September 11, 2017 Open

All Presentations →